Program
This edition will feature the following themes:
- Alternative to current antibiotics & antivirals
- Immunotherapies & new biotherapeutics
- One Health Approach to Tackling Infectious Diseases
- Innovations in human vaccines
- AI & Data-Driven Strategies for Infectious Diseases
- Innovative Biomarkers for Infectious Diseases: From Diagnosis to Theragnosis
2025 Speaker
Erin Duffy
Chief of Research & Development
CARB-X, USA
Lisa Osbelt-Block
Researcher
Helmholtz Center for Infection Research, Germany
Vincent Marechal
Professor
Sorbonne University
Director
National platform OBEPINE+
Mélanie Hamon
Head of the Chromatin and Infection group
Institut Pasteur, France
Helen Bright
CSO
Centauri Therapeutics, United Kingdom
Nicolas Burdin
Global Head of R&D
CloverBiopharmaceuticals, France
Victoria Savage
CSO
Infex Therapeutics Ltd, United Kingdom
Stuart Hannah
CEO
Microplate Dx, Scotland
Khaled Abousaleh
CEO
Zynnon, Switzerland
DAY 1
Thursday, 13 November 2025
8h00
Registration & welcome coffee
8h30
Welcome Address
8h35
Title to be confirmed
Elsa Kress
Head of Business Development
MabDesign, France
8h45
Opening lectures
- Plenary
Chaired by
8h45
Title to be confirmed
Richard White
Professor of Infectious Disease Modelling
London School of Hygiene and Tropical Medicine, United Kingdom
9h15
Modelling to support new TB Vaccine development and (hopefully) introduction
Richard White
Professor of Infectious Disease Modelling
London School of Hygiene and Tropical Medicine, United Kingdom
9h45
Decoding Mycobacterium tuberculosis Diversity: Unlocking New Strategies in TB Control
Sarah Fortune
Chair of Immunology and Infectious Diseases
Harvard T.H. Chan School of Public Health, USA
10h15
Title to be confirmed
Maria Van Kerkhove
Director (a.i.) Department of Epidemic and Pandemic Preparedness and Prevention
World Health Organization, Switzerland
10h45
Coffe Break - Exhibition Hall
11h05
Track 1: One Health Approach to Tackling Infectious Diseases
- Plenary
Chaired by
11h05
OH should be embedded in health policies and strategies
Thierry Lefrançois
Advisor to the CEO
CIRAD, France
11h35
OBEPINE+ platform: tracking epidemics through wastewater analysis
Vincent Marechal
Professor of virology
Sorbonne University, France
Director
National platform OBEPINE+, France
11h55
Novel vaccines for the control of highly avian influenza in poultry
Agnès Dancer
R&D Project Manager
Boehringer Ingelheim, France
11h25
Speaker 3
Yves Briers
CSO
Obulytix - Belgium
12h15
Q&A session
12h25
Lunchbreak - Poster Presentation - B2B Meetings
14h00
Track 2: Innovations in human vaccines
- Plenary
Sponsored by Sanofi
Chaired by
14h00
Clover’s Trimer-Tag vaccines: COVID, RSV and beyond…
Nicolas Burdin
Global Head of R&D
Clover Biopharmaceuticals, France
14h40
The transformative role of open-access adjuvants for human vaccines
Céline Lemoine
Head of VFI Laboratories
Vaccine Formulation Institute (VFI) - Switzerland
15h00
Speaker 4
Stephanie Fanucchi
CSO
Lemba Therapeutics - Netherlands
15h20
Q&A session
15h35
Coffe Break - Exhibition Hall - B2B Meetings 3 slots
16h10
Driving Breakthroughs in Infectious Diseases
16h10
Establishment of a Comprehensive Platform for Empowering the Discovery of Viral Vaccines
Fusen Lin
Research Director
WuXi AppTec - China
16h25
Addressing Delivery Barriers in RNA-based Vaccines through the FlashRNA® Platform
Christine Duthoit
CEO - CSO
RNAlead - France
16h40
ViroID- Breakthrough Approach to Viral Characterization through Nanopore Technology
Léa Chazot-Franguiadakis
Research Engineer
Ecole Normale Supérieure de Lyon - France
16h50
nanoSFERIC: A Novel Flexible Nanoparticle Vaccine Platform
Urban Bezeljak
CEO
Sferogen - Slovenia
17h00
Expanding the Toolbox for Passive Immunotherapy: Comparative Evaluation of Purified, LNP-RNA, and rAAV Antibody Delivery
David Torres
Preclinical Analytics Project Leader
CER Groupe - Belgium
17h10
Discovery and preclinical development of potent human neutralizing antibodies against BK polyomavirus for prophylactic use in kidney transplant recipients
Pascal Poignard
University professor and hospital practitioner
Institut de Biologie Structurale (IBS) - France
17h20
Peptide microarrays as a novel high-throughput tool for mapping HLA class II–peptide interactions - a case study on HCMV epitopes
Dagmar Hildebrand
Head of R&D
PEPperPRINT - Germany
17h30
OVX836, a Nucleoprotein-based vaccine under clinical development, offers protection Against Highly Pathogenic Avian Influenza Viruses (H5N1 and H7N9) in Mouse and Ferret Models
Charlotte Primard
Senior non clinical project manager
Osivax - France
17h40
Real-time Immunological Profiling in Physiological Conditions: Advancing Vaccine and Therapeutic Development with WHITE FOx Technology
Florian Bossard
Scientific Sales Manager
Vixen Bio - France
17h50
Real-Time Detection of Ligand Interactions on Live Bacteria: A Kinetic Study of Antibody Binding
Joao Encarnação
Founder
Adamastor Bioservices - Italy
18h00
From Pathogen Load to Host Response: A Bioluminescent Human Pulmonary ALI Model of KAPE Bacteria for Translational Antimicrobial Screening
Marc Vandamme
R&D program director
ERBC - France
18h10
Evening Cocktail & Networking
18h00
End of DAY 1
DAY 2
Friday, 14 November 2025
8h15
Welcome coffee
8h45
Opening lectures
- Plenary
Chaired by
8h45
Title to be confirmed
Marco Cavaleri
Head of Public Health Threats
European Medicines Agency - Netherlands
9h15
Fighting Antimicrobial Resistance Through Innovation
Vega Masignani
Alliance Director
CARB-X, USA
9h45
Roundtable: Pandemic Preparedness: Threats, Surveillance, and Healthcare Readiness
- Plenary
Animated by IDCluster
Christiane Riedel
Specialist in veterinary medicine and virology
ENS/CIRI, Senegal
Christiane Riedel
Specialist in veterinary medicine and virology
ENS/CIRI, France
Mawlouth Diallo
Head of Unit
Institut Pasteur de Dakar, Senegal
Xavier Lescure
Infectious disease specialist
Hôpital Bichat Claude-Bernard, France
10h30
Coffe Break - Exhibition Hall - B2B Meetings
11h00
Track 3: Immunotherapies & new biotherapeutics
- Plenary
Chaired by
11h00
How bacterial pathogens manipulate host chromatin to modulate immune responses?
Mélanie Hamon
Head of the Chromatin and Infection group
Institut Pasteur, France
11h20
Alphamer®: A Modular Antibody-Recruiting Platform for Infectious Disease
David Chapman
Head of Biology
Centauri Therapeutics, United Kingdom
11h40
RESP-X: A Novel Anti-Virulence Therapy Targeting Pseudomonas aeruginosa in Chronic Infection
Victoria Savage
CSO
Infex Therapeutics Ltd, United Kingdom
12h00
Q&A session
12h15
Lunchbreak - Poster Presentation - B2B Meetings
14h00
Track 4: Alternative to current antibiotics & antivirals
- Plenary
Chaired by
14h00
Competition in the gut: From ecology to novel therapeutics
Lisa Osbelt-Block
Researcher
Helmholtz Center for Infection Research, Germany
14h20
Small Molecule FPR1 Agonists: Boosting the Innate Immune System to Cure Resistant Bacterial Infections
Peter Olofsson-Sahl
Founder and CEO
Inicure AB, Sweden
14h40
RNAs in bacteria-phage interactions: from identification to applications for biotechnology and health
Olga Soutourina
Professor in Microbiology
Paris-Saclay University - France
15h00
Q&A session
15h15
Track 5: Innovative Biomarkers for Infectious Diseases: From Diagnosis to Theragnosis
- Plenary
Chaired by
15h15
RapidPlateTM: A novel, cost-effective, electrochemical, rapid antibiotic susceptibility test for urinary tract infections
Stuart Hannah
CEO
Microplate Dx, Scotland
15h40
Revolutionizing Infectious Disease Diagnostics Through Gas Signatures
Khaled Abousaleh
CEO
Zynnon, Switzerland
15h55
Speaker 3
Antonella Comforti
Principal Investigator
Takis Biotech - Italy
16h05
Track 6: AI & Data-Driven Strategies for Infectious Diseases
- Plenary
Chaired by
15h05
Agentic AI from Biology to Drug Discovery
Maxime Touzot
Head of Medicine
Owkin, France
16h30
Annoucemment of next year edition
16h40
